Cited by

• Impact of an online decision support tool for ductal carcinoma in situ (DCIS) using a pre-post design (AFT-25).

  Ozanne EM, Maves K, Tramontano AC, Lynch T, Thompson A, Partridge A, Frank E, Collyar D, Basila D, Pinto D, Hyslop T, Ryser MD, Rosenberg S, Hwang ES, Punglia RS. Ozanne EM, et al. Breast Cancer Res. 2024 Sep 17;26(1):134. doi: 10.1186/s13058-024-01891-w. Breast Cancer Res. 2024. PMID: 39289750 Free PMC article.
• The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer.

  Berlin A, Ramotar M, Santiago AT, Liu Z, Li J, Wolinsky H, Wallis CJD, Chua MLK, Paner GP, van der Kwast T, Cooperberg MR, Vickers AJ, Urbach DR, Eggener SE. Berlin A, et al. J Natl Cancer Inst. 2023 Nov 8;115(11):1364-1373. doi: 10.1093/jnci/djad108. J Natl Cancer Inst. 2023. PMID: 37285311 Free PMC article.
• Should low-risk DCIS lose the cancer label? An evidence review.

  Ma T, Semsarian CR, Barratt A, Parker L, Pathmanathan N, Nickel B, Bell KJL. Ma T, et al. Breast Cancer Res Treat. 2023 Jun;199(3):415-433. doi: 10.1007/s10549-023-06934-y. Epub 2023 Apr 19. Breast Cancer Res Treat. 2023. PMID: 37074481 Free PMC article. Review.
• Factors associated with ductal carcinoma in situ (DCIS) treatment patterns and patient-reported outcomes across a large integrated health network.

  Kim H, Wang H, Demanelis K, Clump DA, Vargo JA, Keller A, Diego M, Gorantla V, Smith KJ, Rosenzweig MQ. Kim H, et al. Breast Cancer Res Treat. 2023 Feb;197(3):683-692. doi: 10.1007/s10549-022-06831-w. Epub 2022 Dec 17. Breast Cancer Res Treat. 2023. PMID: 36526807 Free PMC article.
• Characterizing the Language Used to Discuss Death in Family Meetings for Critically Ill Infants.

  Barlet MH, Barks MC, Ubel PA, Davis JK, Pollak KI, Kaye EC, Weinfurt KP, Lemmon ME. Barlet MH, et al. JAMA Netw Open. 2022 Oct 3;5(10):e2233722. doi: 10.1001/jamanetworkopen.2022.33722. JAMA Netw Open. 2022. PMID: 36197666 Free PMC article.